First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from 2000 patients treated in the multicentre AVANTI study
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from 2000 patients treated in the multicentre AVANTI study